Published on
January 9, 2025
- 14:00 GMT
Inmagene Reports Positive Topline Results of IMG-007, a Nondepleting Anti-OX40 Monoclonal Antibody with an Extended Half-Life, for ...
A 4-week treatment with IMG-007 resulted in a mean reduction in eczema area and severity index (EASI) of 77% and EASI-75 response of 54%, at week 16 Durable inhibition of inflammatory markers was observed for up to 24 weeks IMG-007’s subcutaneous (SC) …
Distribution channels:
Healthcare & Pharmaceuticals Industry, Technology
...
